Nanobiotix SA

04/02/2024 | Press release | Distributed by Public on 04/02/2024 17:09

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to[...]